Table 2.
Geographical Distribution of Phenotypically Resistant Isolates
| Country | % of Isolates with Resistant Phenotypes (No. Resistant / No. Tested) | ||||||
|---|---|---|---|---|---|---|---|
| CRE | Presumptive ESBL Non-CRE | CAZ-NS | MER-NS | ||||
| KPN | EC | KPN | ENTB | PSA | KPN | PSA | |
| Japan | 0.0%(0/15) | 33.3%(11/33) | 6.7%(1/15) | 33.3%(1/3) | 26.3%(5/19) | 0.0%(0/15) | 26.3%(5/19) |
| Korea | 2.4%(3/123) | 37.3%(81/217) | 40.7%(50/123) | 31.3%(5/16) | 27.2%(22/81) | 2.4%(3/123) | 29.6%(24/81) |
| Malaysia | 9.8%(9/92) | 36.2%(25/69) | 26.1%(24/92) | 38.9%(7/18) | 12.5%(9/72) | 9.8%(9/92) | 22.2%(16/72) |
| Philippines | 20.4%(20/98) | 41.6%(62/149) | 38.8%(38/98) | 47.5%(28/59) | 13.2%(9/68) | 20.4%(20/98) | 10.3%(7/68) |
| Singapore | 0.0%(0/21) | 30.0%(3/10) | 0.0%(0/21) | 33.3%(1/3) | 15.8%(3/19) | 0.0%(0/21) | 15.8%(3/19) |
| Taiwan | 11.1%(7/63) | 40.0%(30/75) | 38.1%(24/63) | 72.7%(16/22) | 10.8%(4/37) | 14.3%(9/63) | 29.7%(11/37) |
| Thailand | 26.8%(26/97) | 51.4%(57/111) | 35.1%(34/97) | 22.6%(7/31) | 27.4%(20/73) | 26.8%(26/97) | 35.6%(26/73) |
| Vietnam | 55.3%(21/38) | 65.4%(34/52) | 10.5%(4/38) | 0.0%(0/0) | 28.6%(2/7) | 57.9%(22/38) | 28.6%(2/7) |
Abbreviations: CRE, carbapenem-resistant Enterobacterales; ESBL, extended-spectrum β-lactamase; CAZ-NS, ceftazidime non-susceptible; MER-NS, meropenem non-susceptible; KPN, Klebsiella pneumoniae; EC, Escherichia coli; ENTB, Enterobacter cloacae species complex; PSA, Pseudomonas aeruginosa.